A proposed conceptual model for orphan drug market entry
Abstract
The right to health is closely linked to the physical in mental well-being of all individuals in is a necessary condition for the realization of additional human rights, including the realization of an adequate standard of living. Rare diseases are diseases that affect a very small proportion of the population in have a special place because of their rarity. They are often chronic, progressive, life-threatening health conditions. Some of them can be treated with medicines called orphan drugs. Orphan drugs are developed by the pharmaceutical industry not for economic reasons, but to meet public health needs. New treatments need to be evaluated before they reach the market. This is done using health technology assessment, which assesses the relative effectiveness of new medicines, medical devices in other health technologies. The market entry of orphan drugs requires the active involvement of all stakeholders: marketing authorisation holders, competent authorities, the medical profession in patient organisations. Model of market entry for orphan drugs was developed using the qualitative methodology of constructivist grounded theory, tailored to the niche market in considers all key categories.
References
Aaker, D. A., and Weinberg, C. B. (1975). Interactive marketing models. Journal of Marketing, 39(43), pp. 16–23.
Abozaid, G. M., Kerr, K., McKnight, A., and Al-Omar, H. A. (2022). Criteria to define rare diseases in orphan drugs: a systematic review protocol. BMJ Open, 12(7), e062126. https://doi.org/10.1136/bmjopen-2022-062126
Althobaiti, H., Seoane-Vazquez, E., Brown, L. M., Fleming, M. L., and Rodríguez-Monguió, R. (2023). Disentangling the cost of orphan drugs marketed in the United States. Multidisciplinary Digital Publishing Institute, 11(4), pp. 558–558. https://doi.org/10.3390/healthcare11040558
Anamul, H., and Alam, Z. (2012). Business analysis of pharmaceutical firms in Bangladesh: Problems in prospects. Journal of Business in Technology (Dhaka), 6(1), pp. 61-77.
Bergen, M., Dutta, S., and Walker, O. C. (1992). Agency relationships in marketing: A review of the implications and applications of agency and related theories. Journal of Marketing, 56(3), pp. 1–24. https://doi.org/10.1177/002224299205600301
Borden, N. H. (1964). The concept of the marketing mix. Journal of Advertising Research, 4(1), pp. 2–7.
Boulden, J. B., and Buffa, E. S. (1970). Corporate models: online real-time systems. Harvard Business Review, 48(4), pp. 65–83.
Brody, H. (2007). Hooked: Ethics, the medical profession, and the pharmaceutical industry. Lanham, MD: Rowman & Littlefield.
Brody, H., and Light, D. W. (2011). The inverse benefit law: how drug marketing undermines patient safety and public health. American Journal of Public Health, 101(3), pp. 399–404.
Charmaz, K. (2014). Constructing grounded theory: A practical guide through qualitative analysis (2nd ed.). London: Sage.
den Exter, A. (2017). The right to healthcare under European law. Diametros, 51, pp. 173-195.
Denzin, N. K., and Lincoln, Y. S. (Ed.). (2005). The handbook of qualitative research (3rd ed.). Thousand Oaks, CA: Sage Publications.
Easterby-Smith, M., Thorpe, R., and Lowe, A. (2005). Raziskovanje v managementu. Koper: Fakulteta za management.
EMA. (2020). Legal framework: orphan designation. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation/legal-framework-orphan-designation (Accessed: April 19, 2021).
EURORDIS. (2007). Survey of the delay in diagnosis for 8 rare diseases in Europe (´EurordisCare2`). Available at: https://www.eurordis.org/sites/default/files/publications/Fact_Sheet_Eurordiscare2.pdf (Accessed: March 8, 2021).
Glaser, B. G., and Strauss, A. L. (1967). The discovery of grounded theory: Strategies for qualitative research. Chicago: Aldine.
Gobburu, J. V. S., and Lesko, L. J. (2009). Quantitative disease, drug, and trial models. Annual Reviews, 49(1), pp. 291–301. https://doi.org/10.1146/annurev.pharmtox.011008.145613
Groft, S. C., Posada, M., and Taruscio, D. (2021). Progress, challenges, and global approaches to rare diseases. Wiley-Blackwell, 110(10), pp. 2711–2716. https://doi.org/10.1111/apa.15974
Jamshed, S. (2014). Qualitative research method-interviewing and observation. Journal of basic and clinical pharmacy 5, pp. 87-88. DOI: 10.4103/0976-0105.141942.
JAZMP. (2021). Homepage. Available at: https://www.jazmp.si/humana-zdravila/farmakovigilanca/ (Accessed: April 19, 2021).
Kehayov, A. (2016). Modern approach in exercising the right to health care. Journal of Medical in Dental Practice, 3, pp. 484–487. https://doi.org/10.18044/Medinform.201632.484
Kesič, D. (2004). Model tržnega prilagajanja farmacevtskih družb iz tranzicijskih držav v procesu globalizacije trga (Doktorska disertacija). Ekonomska fakulteta, Maribor.
Kotler, P., and Keller, K. L. (2016). Marketing management. New Jersey: Pearson Education Limited.
Kronberger, N., and Wagner, W. (2000). Keywords in context: Statistical analysis of text features. v M. W. Bauer in G. Gaskell (Ed.), Qualitative researching with text, image, and sound (pp. 300-317). London: Sage.
Legard, R., Keegan, J., and Ward, K. (2003). In-depth interviews. In J. Ritchie in J. Lewis (Ed.), Qualitative research practice: A guide for social science students and researchers (pp. 139–169). London: Sage Publications.
Lublóy, Á. (2014). Factors affecting the uptake of new medicines: a systematic literature review. BioMed Central, 14(1). https://doi.org/10.1186/1472-6963-14-469
McCarthy, E. J. (1960). Basic marketing: A managerial approach. Homewood, IL: Richard D. Irwin Inc.
McIntyre, S. H. (1982). An experimental study of the impact of judgement-based marketing models. Management Science, 28(1), pp. 17–32.
Montgomery, D. B., and Weinberg, C. B. (1973). Modelling marketing phenomena: A managerial perspective. Journal of Contemporary Business, 2(4), pp. 17–43.
Morgan, H. (2022). Conducting a qualitative document analysis. The Qualitative Report, 27(1), 64-77. https://doi.org/10.46743/2160-3715/2022.5044
Riffenburgh, R. H., and Gillen, D. L. (2020). Statistics in medicine (4th ed.). San Diego, CA: Academic Press.
Ryan, G. W., and Bernard, R. H. (2003). Techniques to identify themes. Field Methods, 15, 85–109. http://dx.doi.org/10.1177/1525822X02239569
Sheiner, L. B., and Steimer, J. L. (2000). Pharmacokinetic/pharmacodynamic modeling in drug development. Annual Reviews, 40(1), 67–95. https://doi.org/10.1146/annurev.pharmtox.40.1.67
Shieh, G. (2010). On the misconception of multicollinearity in detection of moderating effects: Multicollinearity is not always detrimental. Multivariate Behavioral Research, 45(3), pp. 483–507. https://doi.org/10.1080/00273171.2010.483393
Strauss, A. L., and Corbin, J. (1998). The basics of qualitative analysis: Grounded theory procedures and techniques (2nd ed.). Thousand Oaks, CA: Sage.
European Parliament and Council (2000). Regulation (EC) No 141/2000 on orphan medicinal products. Official Journal of the EU, No. L 018.Vukasović, T. (2012). Trženje – od temeljev trženja do strateškega tržnega načrtovanja. Koper: Založba Univerze na Primorskem.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain rights under the Creative Commons Attribution-ShareAlike 4.0 International CC BY-SA 4.0. Authors assign copyright or license the publication rights in their articles, including abstracts, to MIP=JIBM. This enables us to ensure full copyright protection and to disseminate the article, and of course MIP=JIBM, to the widest possible readership in electronic format. Authors are themselves responsible for obtaining permission to reproduce copyright material from other sources.
